Information de reference pour ce titreAccession Number: | 00001574-201611000-00005.
|
Author: | Schubert, Mitchell L.
|
Institution: | Division of Gastroenterology, Department of Medicine, Virginia Commonwealth University Health System, Richmond and Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA
|
Title: | |
Source: | Current Opinion in Gastroenterology. 32(6):452-460, November 2016.
|
Abstract: | Purpose of review: The present review summarizes the past year's literature, both clinical and basic science, regarding neuroendocrine and intracellular regulation of gastric acid secretion and proper use of antisecretory medications.
Recent findings: Gastric acid kills microorganisms, modulates the gut microbiome, assists in digestion of protein, and facilitates absorption of iron, calcium, and vitamin B12. The main stimulants of acid secretion are gastrin, released from antral G cells; histamine, released from oxyntic enterochromaffin-like cells; and acetylcholine, released from antral and oxyntic intramural neurons. Other stimulants include ghrelin, motilin, and hydrogen sulfide. The main inhibitor of acid secretion is somatostatin, released from oxyntic and antral D cells. Glucagon-like peptide-1 also inhibits acid secretion. Proton pump inhibitors (PPIs) reduce acid secretion and, as a result, decrease somatostatin and thus stimulate gastrin secretion. Although considered well tolerated drugs, concerns have been raised this past year regarding associations between PPI use and kidney disease, dementia, and myocardial infarction; the quality of evidence, however, is very low.
Summary: Our understanding of the physiology of gastric secretion and proper use of PPIs continues to advance. Such knowledge is crucial for improved management of acid-peptic disorders.
Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
|
Author Keywords: | gastrin; H+K+-ATPase; histamine; parietal cell; proton pump; proton pump inhibitor; somatostatin.
|
References: | 1. Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut 2015; 10:1650-1668.
2. Waldum HL, Kleveland PM, Fossmark R. Upper gastrointestinal physiology and diseases. Scand J Gastroenterol 2015; 50:649-656.
3[black small square]. Betesh AL, Santa Ana CA, Cole JA, Fordtran JS. Is achlorhydria a cause of iron deficiency anemia? Am J Clin Nutr 2015; 102:9-19.
4. van Aerts RMM, van Deursen CTBM, Koek GH. Proton pump inhibitors reduce the frequency of phlebotomy in patients with hereditary hemochromatosis. Clin Gastroenterol Hepatol 2016; 14:147-152.
5. Haffner-Luntzer M, Heilmann A, Heidler V, et al. Hypochlorhydria-induced calcium malabsorption does not affect fracture healing but increases posttraumatic bone loss in the intact skeleton. J Orthop Res 2016; [Epub ahead of print].
6[black small square]. Levenstein D, Rosenstock S, Kart R, et al. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastro Hepatol 2015; 13:498-506.
7. Marshall KM, Laval M, Sims I, et al. Retro-inverso forms of gastrin5-12 are as biologicallly active as glycine-extended gastrin in vitro but not in vivo. Peptides 2015; 74:16-22.
8. Tripathi S, Flobak A, Chawla K, et al. The gastrin and cholecystokinin receptors mediated signaling network: a scaffold for data analysis and new hypotheses on regulatory mechanisms. BMC Syst Biol 2015; 9:40.
9[black small square]. Rettenberger AT, Schulze W, Breer H, Haid D. Analysis of the protein related receptor GPR92 in G-cells. Front Physiol 2015; 6:261.
10. Grong E, Graeslie H, Munkvold B, et al. Gastrin secretion after bariatric surgery -response to a protein-rich mixed meal following roux-en-Y gastric bypass and sleeve gastrectomy: a pilot study in normoglycemic woman. Obes Surg 2016; 7:1448-1456.
11. Lundell L, Vieth M, Gibson F, et al. Systematic review: the effect of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42:649-663.
12[black small square]. Laval M, Baldwin GS, Shulkes A, Marshall KM. Increased gastrin gene expression provides a physiological advanatage to mice under hypoxic conditions. Am J Physiol Gastrointest Liver Physiol 2015; 308:G76-G84.
13. Rosentraeger MJ, Garbrecht N, Anlauf M, et al. Syndromic versus nonsyndromic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Arch 2016; 468:277-287.
14. Kasajima A, Fujishima F, Morikawa T, et al. G-cell hyperplasia of the stomach induces ECL-cell proliferation in the pyloric glands in a paracrinal manner. Pathol Int 2015; 65:259-263.
15[black small square]. Panula P, Chazot PL, Cowart M, et al. International union of basic and clinical pharmacology. XCVIII. Histamine receptors. Pharmacol Rev 2015; 67:601-655.
16. Vuyyuru L, Schubert ML. Histamine, acting via H3 receptors, inhibits somatostatin and stimulates acid secretion in isolated mouse stomach. Gastroenterology 1997; 113:1545-1552.
17. Engelstoft MS, Lund ML, Grunddal KV, et al. Research resource: a chromogranin A reporter for serotonin and histamine secreting enteroendocrine cells. Mol Endocrinol 2015; 29:1658-1671.
18. Laermans J, Vancleef L, Tack J, Depoortere I. Role of the clock gene Bmal1 and the gastric ghrelin-secreting cell in the circadian regulation of the ghrelin-GOAT system. Sci Rep 2015; 5:16748.
19. Goswami C, Shimada Y, Yoshimura M, et al. Motilin stimulates gastric acid secretion in coordination with ghrelin in Suncus murinus. PloS ONE 2015; 10:e0131554.
20. Sun H, Zhang J, Shi Y, et al. Effect of exogenous hydrogen sulfide on gastric acid secretion. J Gastroenterol Hepatol 2016; 31:1280-1283.
21[black small square]. Egerod KL, Engelstoft MS, Lund ML, et al. Transcriptional and functional characterization of the G protein-coupled receptor repertoire of gastric somatostatin cells. Endocrinology 2015; 156:3909-3923.
22. Adriaenssens A, Lam BYH, Billing L, et al. A transcriptome-led exploration of molecular mechanisms regulating somatostatin-producing D-cells in the gastric epithelium. Endocrinology 2015; 156:3924-3936.
23. Smits MM, Tonneijck L, Muskiet MHA, et al. Gastrointestinal actions of GLP-1 based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab 2016; 18:224-235.
24[black small square]. Abdul-Hussein M, Freeman J, Castell D. Concomitant administration of a histamine2 receptor antagonist and proton pump inhibitor enhances gastric acid suppression. Pharmacotherapy 2015; 35:1124-1129.
25. Fujii T, Takahashi Y, Takeshima H, et al. Inhibition of gastric H+,K+-ATPase by 4-(2-butyl-6,7-dichloro-2-cyclopentylindan-1-on-5-yl)oxybutyric acid (DCPIB), an inhibitor of volume-regulated anion channel. Eur J Pharmacol 2015; 765:34-41.
26. Hwang IY, Jeong CS. Gastroprotective activities of sennoside A and sennoside B via the up-regulation of prostaglandin E2 and the inhibition of H+/K+-ATPase. Biomol Ther 2015; 23:458-464.
27[black small square][black small square]. Hammond CE, Beeson C, Suarez G, et al. Helicobacter pylori virulence factors affecting gastric proton pump expression and acid secretion. Am J Physiol Gastrointest Liver Physiol 2015; 309:G193-G201.
28[black small square][black small square]. Jiang H, Wang W, Zhang Y, et al. Cell polarity kinase MST4 cooperates with cAMP-dependent kinase to orchestrate histamine-stimulated acid secretion in gastric parietal cells. J Biol Chem 2015; 47:28272-28285.
29. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016; 176:238-246.
30. Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol 2016; 73:410-416.
31. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLOS ONE 2015; 10:e0124653.
32. Khan MA, Kamal S, Khan S, et al. Systematic review and meta-analysis of the possible association between pharmacological gastric acid suppression and spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2015; 27:1327-1336.
33. Wang YP, Liu CJ, Chen TJ, et al. Proton pump inhibitor use significantly increases the risk of cryptogenic liver abscess: a population-based study. Aliment Pharmacol Ther 2015; 41:1775-1781.
34. Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther 2015; 41:1162-1174.
35. Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol 2015; 6:E89.
36[black small square]. Freeberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 2015; 149:883-885.
37. Melgar S, Nieuwdorp M. Are proton pump inhibitors affecting intestinal microbiota health. Gastroenterology 2015; 149:848-850.
38. Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2015; 65:749-756.
39. Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase. Aliment Pharmacol Ther 2015; 42:1315-1326.
40. Sakurai Y, Mori Y, Okamoto H, et al. Randomised clinical trial: acid-inhibitory effect of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomized open-label cross-over study. Aliment Pharmacol Ther 2016; 43:240-251.
41. Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015; 42:685-695.
42[black small square]. Yuan J, Liu W, Karvar S, et al. Potassium channel KCNJ15 is required for histamine-stimulated gastric acid secretion. Am J Physiol Cell Physiol 2015; 309:C264-C270.
43. Nighot MP, Nighot PK, Ma TY, et al. Genetic ablation of the ClC-1 Cl- channel disrupts mouse gastric parietal cell acid secretion. PLos One 2015; 10:e0138174.
|
Language: | English.
|
Document Type: | STOMACH AND DUODENUM: Edited by Mitchell L. Schubert.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0267-1379
|
NLM Journal Code: | 8506887
|
DOI Number: | https://dx.doi.org/10.1097/MOG.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|